Rapid Micro Biosystems (RPID)
NASDAQ:RPID
Want to see RPID full AI Analyst Report?
Top Page
Rapid Micro Biosystems
(NASDAQ:RPID)
Select Model
Select Model
Rating:47Neutral
Price Target:
$2.50
▲(9.65% Upside)
Action:ReiteratedDate:04/23/26
The score is held down primarily by weak financial fundamentals—large ongoing losses, negative operating/free cash flow, and reduced balance-sheet cushion. The earnings call improves the outlook with credible growth and margin guidance plus strong commercial momentum, but technicals remain broadly bearish and valuation lacks support due to negative earnings and no dividend.
Positive Factors
Recurring revenue mix
A majority recurring revenue base (53%) with consumables up 17% creates predictable, annuity-like cash flows that scale with installed systems. Over 2–6 months this improves revenue visibility, supports margin leverage as service sales grow, and reduces reliance on lumpy instrument sales.
Negative Factors
Persistent cash burn
Consistent negative operating and free cash flow implies ongoing reliance on external financing or equity issuance. Over months this constrains strategic flexibility, increases dilution/refinancing risk, and limits ability to invest in sales, validation support, or product roadmaps without improved cash generation.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring revenue mix
A majority recurring revenue base (53%) with consumables up 17% creates predictable, annuity-like cash flows that scale with installed systems. Over 2–6 months this improves revenue visibility, supports margin leverage as service sales grow, and reduces reliance on lumpy instrument sales.
Read all positive factors
Rapid Micro Biosystems (RPID) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$113.96M
Dividend YieldN/A
Average Volume (3M)253.56K
Price to Earnings (P/E)―
Beta (1Y)1.09
Revenue Growth19.74%
EPS Growth1.76%
CountryUS
Employees163
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-1.06
Shares Outstanding41,267,510
10 Day Avg. Volume146,703
30 Day Avg. Volume253,557
Financial Highlights & Ratios
PEG Ratio0.99
Price to Book (P/B)3.90
Price to Sales (P/S)3.86
P/FCF Ratio-4.06
Enterprise Value/Market Cap1.03
Enterprise Value/Revenue3.49
Enterprise Value/Gross Profit20.11
Enterprise Value/Ebitda-2.66
Forecast
1Y Price Target
$8.00Price Target Upside250.88% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.94
Revenue Forecast (FY)$39.27M
Rapid Micro Biosystems Business Overview & Revenue Model
Company Description
Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, medical devices, and personal care products in North America, Europe, and Asia. ...
How the Company Makes Money
Rapid Micro Biosystems makes money primarily by selling its automated microbial detection platform and generating recurring revenue from ongoing consumables and services tied to the installed base. Key revenue streams include: (1) Product revenue ...
Rapid Micro Biosystems Earnings Call Summary
Earnings Call Date:Mar 12, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 07, 2026
Earnings Call Sentiment Positive
The call balanced meaningful commercial momentum and tangible improvement initiatives against near-term operational and margin headwinds. Highlights include record quarterly revenue (+37% YoY), a strong increase in product revenue (+78% Q4), expanding strategic partnerships (Samsung, Amgen, MilliporeSigma), an installed base of 190 systems (155 validated), locked-in consumable cost reductions, and a concrete 2026 guide ($37M–$41M, ~20% gross margin). Lowlights center on a $1.1M inventory write-off that drove Q4 product margin to negative 8% and total gross margin to negative 3%, softer service revenue and margin, a widening placed-to-validated gap (timing risk), and an increased Q4 net loss ($12.5M). Management provided a clear pathway to margin recovery (cost reductions and service leverage) and set prudent guidance that incorporates timing uncertainty.Positive Updates
Record Quarterly Revenue
Total Q4 revenue of $11.3M, a 37% year-over-year increase (Q4 2024: $8.2M) and a quarterly record; company noted 13 consecutive quarters of meeting or exceeding guidance.
Negative Updates
Inventory-Related Charge and Product Margin Impact
Recorded a $1.1M write-off of unusable consumable inventory in Q4, which reduced product margin by ~12 percentage points; reported Q4 product margin was negative 8% (which would have been +4% excluding the charge).
Read all updates
Q4-2025 Updates
Positive
Negative
Record Quarterly Revenue
Total Q4 revenue of $11.3M, a 37% year-over-year increase (Q4 2024: $8.2M) and a quarterly record; company noted 13 consecutive quarters of meeting or exceeding guidance.
Read all positive updates
Company Guidance
Management guided full-year 2026 revenue of $37–$41 million and 30–38 system placements, with roughly 20% total gross margin for the year (Q4 exit in the mid‑20% range), product margin in the high single-digits to low teens and service margin above 40%; Q1 guidance is at least $7.5 million of revenue and at least 5 system placements with Q1 gross margin in the mid‑single digits (product margin negative single digits, service margin >30%); they expect at least 25 validations in 2026 (≥3 in Q1), at least 30% of placements in H1 and seasonal peak placements in Q4; operating expenses are forecast at $47–$51 million, noncash expenses ~$10 million (≈$3M D&A, $7M stock compensation), CapEx ~$2M, interest income ~$1M and interest expense ~$2M; guidance builds on Q4 2025 results of $11.3M revenue (+37% YoY), 16 systems placed (190 systems placed year‑end, 155 validated), product revenue $9.3M (+78%), consumables +17% for the year, recurring revenue +15% to 53% of total, Q4 product margin -8% (including a $1.1M consumable write‑off; ex‑charge +4%), Q4 total gross margin -3% (ex‑charge +7%), $39M cash and investments, $25M unused debt capacity and $3M net cash burn in Q4.Rapid Micro Biosystems Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
56
Neutral
Cash Flow
28
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 33.59M | 28.05M | 22.52M | 17.13M | 23.23M |
| Gross Profit | 7.61M | -109.00K | -5.49M | -8.54M | -7.74M |
| EBITDA | -44.14M | -46.56M | -53.46M | -60.38M | -45.70M |
| Net Income | -47.12M | -46.89M | -52.47M | -60.81M | -73.52M |
Balance Sheet | |||||
| Total Assets | 74.85M | 98.17M | 143.45M | 190.65M | 241.17M |
| Cash, Cash Equivalents and Short-Term Investments | 38.30M | 50.73M | 92.05M | 108.65M | 193.50M |
| Total Debt | 23.87M | 6.17M | 7.35M | 7.97M | 0.00 |
| Total Liabilities | 41.65M | 22.82M | 25.46M | 26.48M | 20.19M |
| Stockholders Equity | 33.21M | 75.35M | 117.99M | 164.17M | 220.98M |
Cash Flow | |||||
| Free Cash Flow | -31.91M | -45.52M | -46.93M | -65.29M | -58.18M |
| Operating Cash Flow | -31.06M | -44.15M | -45.08M | -58.55M | -54.96M |
| Investing Cash Flow | 14.33M | 36.66M | 42.15M | -93.47M | -13.29M |
| Financing Cash Flow | 19.77M | 203.00K | 149.00K | 693.00K | 216.75M |
Rapid Micro Biosystems Technical Analysis
Neutral
2.28
Price Trends
3.22
Negative
3.48
Negative
3.36
Negative
Market Momentum
-0.27
Negative
39.90
Neutral
57.82
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RPID, the sentiment is Neutral. The current price of 2.28 is above the 20-day moving average (MA) of 2.25, below the 50-day MA of 3.22, and below the 200-day MA of 3.36, indicating a neutral trend. The MACD of -0.27 indicates Negative momentum. The RSI at 39.90 is Neutral, neither overbought nor oversold. The STOCH value of 57.82 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for RPID.
Rapid Micro Biosystems Risk Analysis
Rapid Micro Biosystems disclosed 69 risk factors in its most recent earnings report. Rapid Micro Biosystems reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Rapid Micro Biosystems Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $178.32M | -3.90 | -97.38% | ― | 5.22% | 20.85% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $113.96M | -2.59 | -68.83% | ― | 19.74% | 1.76% | |
47 Neutral | $193.21M | -1.71 | -591.09% | ― | 8.28% | 23.32% | |
46 Neutral | $227.91M | -25.28 | -55.72% | ― | -3.13% | 27.99% | |
45 Neutral | $67.30M | -24.07 | 197.15% | ― | 9.24% | -6.71% | |
43 Neutral | $56.18M | -0.99 | -82.79% | ― | 1.23% | 10.65% |
* Healthcare Sector Average
RPID
Rapid Micro Biosystems
2.49
0.20
8.73%
LUNG
Pulmonx
1.33
-2.11
-61.34%
LNSR
LENSAR
5.56
-8.29
-59.86%
HYPR
Hyperfine
1.81
1.14
168.95%
SGHT
Sight Sciences
4.22
1.41
50.18%
LUCD
Lucid Diagnostics
1.09
-0.14
-11.38%
Rapid Micro Biosystems Corporate Events
Business Operations and StrategyExecutive/Board Changes
Rapid Micro Biosystems Announces COO Transition and Consulting Role
Neutral
Mar 27, 2026
On March 23, 2026, Rapid Micro Biosystems announced that Chief Operating Officer John Wilson intends to depart the company effective April 10, 2026, citing a desire to spend more time with his family and with no disagreements regarding company ope...
Business Operations and StrategyFinancial Disclosures
Rapid Micro Biosystems Posts Record 2025 Results, Guides Higher
Positive
Mar 12, 2026
On March 12, 2026, Rapid Micro Biosystems reported record results for the fourth quarter and full year 2025, with Q4 revenue rising 37% year over year to $11.3 million and full-year revenue up 20% to $33.6 million, driven by increased product and ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.